• 1
    Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004; 10: 16707.
  • 2
    Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, Pachinger W, Aubock J, Fritsch P, Kerl H, Wolff K. Adjuvant interferon alpha-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998; 16: 14259.
  • 3
    Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, Punt CJ, Delauney M, Sales F, Groenewegen G, Ruiter DJ, Jagiello I, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alpha-2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005; 366: 118996.
  • 4
    Verma S, Quirt I, McCready D, Bak K, Charette M, Iscoe N. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006; 106: 143142.
  • 5
    Trefzer U, Hofmann M, Sterry W. [Cutaneous side effects of clinically relevant cytokine therapies]. Dtsch Med Wochenschr 2003; 128: 17827.
  • 6
    Guillot B, Blazquez L, Bessis D, Dereure O, Guilhou JJ. A prospective study of cutaneous adverse events induced by low-dose alpha-interferon treatment for malignant melanoma. Dermatology 2004; 208: 4954.
  • 7
    Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology 2006; 43: 66172.
  • 8
    Dourakis SP, Deutsch M, Hadziyannis SJ. Immune thrombocytopenia and alpha-interferon therapy. J Hepatol 1996; 25: 9725.
  • 9
    Zuffa E, Vianelli N, Martinelli G, Tazzari P, Cavo M, Tura S. Autoimmune mediated thrombocytopenia associated with the use of interferon-alpha in chronic myeloid leukemia. Haematologica 1996; 81: 5335.
  • 10
    Becker JC, Winkler B, Klingert S, Brocker EB. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer 1994; 73: 16214.
  • 11
    Kalkner KM, Ronnblom L, Karlsson Parra AK, Bengtsson M, Olsson Y, Oberg K. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. QJM 1998; 91: 3939.
  • 12
    Betterle C, Fabris P, Zanchetta R, Pedini B, Tositti G, Bosi E, de Lalla F. Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection. Diabetes Care 2000; 23: 117781.
  • 13
    Dumoulin FL, Leifeld L, Sauerbruch T, Spengler U. Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. Biomed Pharmacother 1999; 53: 24254.
  • 14
    Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354: 70918.
  • 15
    Gutzmer R, Kaspari M, Brodersen JP, Mommert S, Voelker B, Kapp A, Werfel T, Kiehl P. Specificity of tyrosinase and HMB45 PCR in the detection of melanoma metastases in sentinel lymph node biopsies. Histopathology 2002; 41: 51018.
  • 16
    Kaufmann R, Tilgen W, Garbe C. [Malignant melanoma. Quality Assurance Committee of the German Society of Dermatology and the Professional Organization of German Dermatologists e. V.] Hautarzt 1998; 48( Suppl 1): S30S38.
  • 17
    Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A,Jr, Kirkwood JM, McMasters KM, Mihm MF, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 363548.
  • 18
    Bystryn JC, Rigel D, Friedman RJ, Kopf A. Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 1987; 123: 10535.
  • 19
    Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 1983; 9: 68996.
  • 20
    Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001; 19: 347782.
  • 21
    Franzke A, Peest D, Probst-Kepper M, Buer J, Kirchner GI, Brabant G, Kirchner H, Ganser A, Atzpodien J. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol 1999; 17: 52933.
  • 22
    Raanani P, Ben Bassat I. Immune-mediated complications during interferon therapy in hematological patients. Acta Haematol 2002; 107: 13344.
  • 23
    Silvestri F, Virgolini L, Mazzolini A, Bertolissi F, Russo D, Fanin R, Baccarani M. Development of autoimmune thyroid diseases during long-term treatment of hematological malignancies with alpha-interferons. Haematologica 1994; 79: 36770.
  • 24
    Fried MW. Side effects of therapy of hepatitis C and their management Hepatology 2002; 36: S237S244.
  • 25
    Bini EJ, Mehandru S. Incidence of thyroid dysfunction during interferon alpha-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study. Arch Intern Med 2004; 164: 23716.
  • 26
    Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87: 48999.
  • 27
    Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid 2003; 13: 54751.